Mylan (MYL) Launches Generic Version of Astra's (AZN) Atacand HCT
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 16/12.5 mg, 32/12.5 mg and 32/25 mg. This product is the generic version of AstraZeneca's (NYSE: AZN) Atacand HCT, and is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.(1)
Mylan was the first company to have submitted a substantially complete ANDA to the FDA containing a Paragraph IV certification for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 32/25 mg, and was awarded 180 days of generic drug marketing exclusivity for this product strength. Mylan is shipping all approved strengths of this product immediately.
Atacand HCT had U.S. sales of $56.3 million for the 12 months ending Sept. 30, 2012, according to IMS Health.
Currently, Mylan has 178 ANDAs pending FDA approval representing $80.1 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Mylan was the first company to have submitted a substantially complete ANDA to the FDA containing a Paragraph IV certification for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 32/25 mg, and was awarded 180 days of generic drug marketing exclusivity for this product strength. Mylan is shipping all approved strengths of this product immediately.
Atacand HCT had U.S. sales of $56.3 million for the 12 months ending Sept. 30, 2012, according to IMS Health.
Currently, Mylan has 178 ANDAs pending FDA approval representing $80.1 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- James Hardie sells Fermacell unit to Holcim for €840 million
- Provident Financial prices $175M subordinated notes at 6.50%
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
